Alpha-dihydroergocryptine in Parkinson's disease: a multiceuntre randomized double blind parallel group study
Data up to Jan 2025
Total Citations Per Year
Abstract
References (35)
“Mini-mental state”
1975 • 82,784 citations
Parkinsonism
1967 • 11,463 citations
SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE
1977 • 585 citations
A METHOD FOR EVALUATING DISABILITY IN PATIENTS WITH PARKINSONʼS DISEASE
1961 • 218 citations
Lisuride, a dopamine agonist in the treatment of early Parkinson's disease
1989 • 131 citations
Recent Advances in Parkinson's Disease.
1972 • 106 citations
Dopamine agonists used as monotherapy in de novo PD patients: comparisons with selegiline.
1992 • 100 citations
Current Status of Dopamine Agonists in Parkinson??s Disease Management
1993 • 68 citations
An algorithm for the management of Parkinson's disease.
1994 • 63 citations
Cabergoline in Parkinson's disease
1993 • 62 citations
Lisuride versus bromocriptine treatment in Parkinson disease
1982 • 61 citations
Lisuride in parkinsonism
1981 • 51 citations
Dopaminergic agonists in the treatment of Parkinson's disease.
1990 • 49 citations
Managing the late complications of Parkinson's disease
1997 • 44 citations
Influence of aging and drug treatment on the cerebral glutathione system
1988 • 43 citations
Dopamine receptor profile of co-dergocrine (Hydergine ®) and its components
1982 • 38 citations
Multicenter study of cabergoline, a long‐acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa
1993 • 38 citations
Lisuride in parkinsonism
1981 • 37 citations
Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease
1992 • 33 citations
Levodopa: Pharmacology, Pharmacokinetics, and Pharmacodynamics
1992 • 31 citations
Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease.
1992 • 27 citations
Experimental Parkinson's disease in monkeys. Effect of ergot alkaloid derivative on lipid peroxidation in different brain areas
1993 • 24 citations
D-2 Dopamine Receptor Activation Reduces Free [3H]Arachidonate Release Induced by Hypophysiotropic Peptides in Anterior Pituitary Cells*
1989 • 24 citations
Second generation of dopamine agonists: pros and cons.
1995 • 22 citations
Advances in neurology, Vol. 53, Parkinson's disease: anatomy, pathology, and therapy
1991 • 20 citations
Madopar HBS in fluctuating parkinsonian patients: Two‐year treatment
1988 • 19 citations
Optimization of levodopa therapy.
1992 • 18 citations
Treatment of Parkinson's Disease
1993 • 16 citations
A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
1987 • 14 citations
Neuroprotective effects of ?-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,3,3,6-tetrahydropyridine
1993 • 13 citations
New strategies in the treatment of early Parkinson's disease
1991 • 13 citations
The inhibition of peroxide formation as a possible substrate for the neuroprotective action of dihydroergocryptine.
1995 • 7 citations
PHARMACOKINETIC AND METABOLISM STUDY IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF SINGLE ORAL DOSE OF 3H-α-DIHYDROERGOCRYPTINE MESYLATE
1996 • 6 citations
Treatment of Parkinson's disease.
1993 • 5 citations
Pharmacokinetics of α‐dihydroergocriptine in rats after single intravenous and single and repeated oral administrations
1995 • 2 citations
Cited By (0)
No citing papers found in database